1. Home
  2. ANIX vs TISI Comparison

ANIX vs TISI Comparison

Compare ANIX & TISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.74

Market Cap

114.0M

Sector

Health Care

ML Signal

HOLD

Logo Team Inc.

TISI

Team Inc.

HOLD

Current Price

$27.96

Market Cap

101.4M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
TISI
Founded
1982
1973
Country
United States
United States
Employees
N/A
6800
Industry
Biotechnology: Pharmaceutical Preparations
Other Consumer Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
114.0M
101.4M
IPO Year
2013
1995

Fundamental Metrics

Financial Performance
Metric
ANIX
TISI
Price
$2.74
$27.96
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$8.67
N/A
AVG Volume (30 Days)
332.0K
28.9K
Earning Date
05-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
N/A
EPS
N/A
N/A
Revenue
$210,000.00
$896,483,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.19
52 Week Low
$2.32
$12.34
52 Week High
$5.46
$28.10

Technical Indicators

Market Signals
Indicator
ANIX
TISI
Relative Strength Index (RSI) 34.69 68.77
Support Level $2.37 $15.93
Resistance Level $3.09 $28.05
Average True Range (ATR) 0.19 1.29
MACD -0.05 -0.13
Stochastic Oscillator 15.89 73.22

Price Performance

Historical Comparison
ANIX
TISI

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About TISI Team Inc.

Team Inc provides specialty industrial services, including inspection, engineering assessment, and mechanical repair and remediation required in maintaining high-temperature and high-pressure piping systems and vessels utilized in refining, petrochemicals, and others. The company operates in two segments, Inspection and Heat Treating and Mechanical Services. The Inspection and Heat Treating segment, which generates maximum revenue, provides conventional and non-destructive testing services for the process, pipeline, and power sectors, pipeline integrity management services, and field heat treating services, as well as associated engineering and condition assessment services. Geographically, the company derives its key revenue from the United States, followed by other countries, and Canada.

Share on Social Networks: